Daily Newsletter

23 August 2024

Daily Newsletter

23 August 2024

University of Eastern Finland develops breast cancer screening algorithm

The AI algorithm holds potential to transform radiological practices by improving mammogram density assessment.

Archana Rani August 23 2024

A research team from the University of Eastern Finland has developed MV-DEFEAT, an AI algorithm, to enhance breast cancer screening accuracy.

The AI algorithm holds the potential to transform radiological practices by improving mammogram density assessment.

It utilises deep learning techniques to evaluate multiple mammogram views simultaneously, closely mirroring the decision-making process of radiologists.

Precise mammography interpretation is essential for breast cancer screening, but obstacles such as inconsistent radiological assessments and a global radiology deficit make this difficult.

The research team, including doctoral researcher Gudhe Raju and senior researcher Hamid Behravan, employed a multi-view deep evidential fusion approach, as part of a study.

This method combines elements of the Dempster-Shafer evidential theory and subjective logic to provide a comprehensive analysis of mammogram images from multiple views.

MV-DEFEAT has demonstrated a 50.78% improvement in distinguishing between benign and malignant tumours over existing multi-view approaches, using the public VinDr-Mammo dataset, which contains more than 10,000 mammograms.

The algorithm's effectiveness has been consistent across different datasets, indicating its robust performance and adaptability to diverse patient demographics.

Its gradient-based saliency maps highlight regions of interest within the mammograms, aiding radiologists in decision-making.

These results highlight the potential of AI to enhance diagnostic processes, potentially leading to earlier detection and improved patient outcomes in breast cancer care.

Raju said: “To fully integrate AI like MV-DEFEAT into clinical practice, it is crucial to build trust among healthcare professionals through rigorous testing and validation. Indeed, our next steps involve further validation studies to establish MV-DEFEAT as a reliable tool for breast cancer diagnostics in Finland.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close